Chemotherapy-induced cardiotoxicity (Q34258080)

31 July 2017

title

Chemotherapy-induced cardiotoxicity. (English)

1 reference

31 July 2017

1 reference

Amir Y Shaikh

1

1 reference

31 July 2017

Jeffrey A Shih

series ordinal

2

1 reference

31 July 2017

publication date

1 June 2012

1 reference

Current heart failure reports

31 July 2017

published in

1 reference

31 July 2017

volume

9

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

117-127

1 reference

Anticancer therapy induced cardiotoxicity: review of the literature

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Cancer therapy-associated cardiotoxicity and signaling in the myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Chronic health conditions in adult survivors of childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Cardiac dysfunction in the trastuzumab clinical trials experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Why do kinase inhibitors cause cardiotoxicity and what can be done about it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

High-dose ifosfamide is associated with severe, reversible cardiac dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Adjuvant docetaxel for node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Chemotherapy agents and hypertension: a focus on angiogenesis blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Effect of Arsenic Trioxide on QT Interval in Patients With Advanced Malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Review of tests for monitoring doxorubicin-induced cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Cardiac diastolic function in pediatric patients receiving doxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Exercise echocardiography in the detection of anthracycline cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Early detection and prediction of cardiotoxicity in chemotherapy-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

A clinicopathologic analysis of adriamycin cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Protective effects of carvedilol against anthracycline-induced cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Effects of doxorubicin-containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Doxorubicin-induced cardiomyopathy treated with carvedilol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Heart transplantation for doxorubicin-induced congestive heart failure in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-012-0083-Y

Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer

21 January 2018

1 reference

12 December 2020

Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure

1 reference

12 December 2020

A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine

1 reference

12 December 2020

Role of biomarkers in cardioncology

1 reference

12 December 2020

Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas

1 reference

12 December 2020

Heart transplantation is a valid therapeutic option for anthracycline cardiomyopathy

1 reference

12 December 2020

Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics

1 reference

12 December 2020

Cardioprotective interventions for cancer patients receiving anthracyclines

1 reference

12 December 2020

Doxorubicin-induced cardiomyopathy

1 reference

12 December 2020

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment

1 reference

12 December 2020

Mitoxantrone: an overview of safety and toxicity

1 reference

12 December 2020

Captopril ameliorates myocardial and hematological toxicities induced by adriamycin

1 reference

12 December 2020

Anthracycline-induced cardiotoxicity

1 reference

12 December 2020

Different anthracycline derivates for reducing cardiotoxicity in cancer patients

1 reference

12 December 2020

Clinical management of doxorubicin-induced heart failure.

1 reference

12 December 2020

Beta-blockade in adriamycin-induced cardiomyopathy

1 reference

12 December 2020

Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab.

1 reference

12 December 2020

10.1007/S11897-012-0083-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1049361315

0 references

1 reference